Tumor cell endocytic machinery

The tumor cell endocytic machinery encompasses the diverse pathways—including clathrin-mediated endocytosis (CME), caveolae-mediated endocytosis, and macropinocytosis—that cancer cells employ to internalize nutrients, ligands, and membrane proteins. This system is frequently hijacked in malignancy to drive constitutive signaling by preventing the degradation of growth factor receptors or by promoting the uptake of extracellular proteins to fuel metabolic demands (Mellman & Yarden, 2013). Beyond its role in tumor progression, the endocytic machinery is the primary gateway for the internalization of antibody-drug conjugates (ADCs) and nanoparticle-based therapeutics, making its activity a key determinant of drug efficacy (Conner & Schmid, 2003). Targeting specific components of this machinery, such as dynamin or clathrin, aims to disrupt these survival pathways, although achieving selectivity over healthy cells remains a significant challenge. Small molecule inhibitors like Dynasore and Pitstop 2 have been developed to probe these processes, though their clinical utility is limited by off-target effects (Macia et al., 2006). Consequently, the endocytic capacity of a tumor is often evaluated as a biomarker for predicting the success of ligand-targeted delivery systems (Doherty & McMahon, 2009). Understanding the spatial and temporal regulation of these pathways is essential for developing next-generation therapies that can specifically exploit the altered endocytic landscape of cancer cells.

Other names

Endocytic pathwayCancer cell endocytosisReceptor-mediated endocytosis machineryMacropinocytosis machineryClathrin-mediated endocytosis system

Inhibition of dynamin-mediated membrane fission, clathrin-coated pit assembly, or actin-dependent macropinocytosis to block nutrient uptake and receptor internalisation; exploitation of endocytic pathways for the intracellular delivery of cytotoxic payloads via antibody-drug conjugates.